Skip to main content
Erschienen in: Applied Health Economics and Health Policy 1/2006

01.03.2006 | Original Research Article

Using economic analyses for local priority setting

The population cost-impact approach

verfasst von: Professor Richard F. Heller, Islay Gemmell, Edward C. F. Wilson, Richard Fordham, Richard D. Smith

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Standard methods of economic analysis may not be suitable for local decision making that is specific to a particular population.

Background

We describe a new three-step methodology, termed ‘population cost-impact analysis’, which provides a population perspective to the costs and benefits of alternative interventions. The first two steps involve calculating the population impact and the costs of the proposed interventions relevant to local conditions. This involves the calculation of population impact measures (which have been previously described but are not currently used extensively) — measures of absolute risk and risk reduction, applied to a population denominator. In step three, preferences of policy-makers are obtained. This is in contrast to the QALY approach in which quality weights are obtained as a part of the measurement of benefit.

Methods

We applied the population cost-impact analysis method to a comparison of two interventions — increasing the use of β-adrenoceptor antagonists (β-blockers) and smoking cessation — after myocardial infarction in a scaled-back notional local population of 100 000 people in England. Twenty-two public health professionals were asked via a questionnaire to rank the order in which they would implement four interventions. They were given information on both population cost impact and QALYs for each intervention.

Results

In a population of 100 000 people, moving from current to best practice for β-adrenoceptor antagonists and smoking cessation will prevent 11 and 4 deaths (or gain of 127 or 42 life-years), respectively. The cost per event prevented in the next year, or life-year gained, is less for β-adrenoceptor antagonists than for smoking cessation. Public health professionals were found to be more inclined to rank alternative interventions according to the population cost impact than the QALY approach.

Discussion

The use of the population cost-impact approach allows information on the benefits of moving from current to best practice to be presented in terms of the benefits and costs to a particular population. The process for deciding between alternative interventions in a prioritisation exercise may differ according to the local context. We suggest that the valuation of the benefit is performed after the benefits have been quantified and that it takes into account local issues relevant to prioritisation. It would be an appropriate next step to experiment with, and formalise, this part of the population cost-impact analysis to provide a standardised approach for determining willingness to pay and provide a ranking of priorities.

Conclusion

Our method adds a new dimension to economic analysis, the ability to identify costs and benefits of potential interventions to a defined population, which may be of considerable use for policy makers working at the local level.
Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
1The use of quotation marks around the term ‘cost per event prevented in your population over the duration of treatment benefit’ is to indicate the new measure described in this article.
 
Literatur
1.
Zurück zum Zitat Wanless D. Securing good health for the whole population. London: HMSO, 2004 Wanless D. Securing good health for the whole population. London: HMSO, 2004
2.
Zurück zum Zitat Coast J. Is economic evaluation in touch with society’s health values? BMJ 2004; 329(7476): 1233–6PubMedCrossRef Coast J. Is economic evaluation in touch with society’s health values? BMJ 2004; 329(7476): 1233–6PubMedCrossRef
3.
4.
Zurück zum Zitat Smith J, Dixon J, Mays N, et al. Practice based commissioning: applying the research evidence. BMJ 2005; 331: 1397–9PubMedCrossRef Smith J, Dixon J, Mays N, et al. Practice based commissioning: applying the research evidence. BMJ 2005; 331: 1397–9PubMedCrossRef
5.
Zurück zum Zitat Oliver A. Putting the quality into quality-adjusted life years. J Public Health Med 2003; 25(1): 8–12PubMedCrossRef Oliver A. Putting the quality into quality-adjusted life years. J Public Health Med 2003; 25(1): 8–12PubMedCrossRef
6.
Zurück zum Zitat Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329(7459): 224–7PubMedCrossRef Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004; 329(7459): 224–7PubMedCrossRef
7.
Zurück zum Zitat Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003; 21(3): 149–57PubMedCrossRef Gafni A, Birch S. NICE methodological guidelines and decision making in the National Health Service in England and Wales. Pharmacoeconomics 2003; 21(3): 149–57PubMedCrossRef
8.
Zurück zum Zitat Maynard A, Bloor K, Freemantle N. Challenges for the national institute for clinical excellence. BMJ 2004; 329(7459): 227–9PubMedCrossRef Maynard A, Bloor K, Freemantle N. Challenges for the national institute for clinical excellence. BMJ 2004; 329(7459): 227–9PubMedCrossRef
10.
Zurück zum Zitat Wilson E, Rees J, Fordham R. Developing a prioritisation framework in an English Primary Care Trust. Cost Eff Resour Alloc 2006; 4(1): 3PubMedCrossRef Wilson E, Rees J, Fordham R. Developing a prioritisation framework in an English Primary Care Trust. Cost Eff Resour Alloc 2006; 4(1): 3PubMedCrossRef
11.
Zurück zum Zitat Heller RF, Dobson AJ. Disease impact number and population impact number: a population perspective to measures of risk and benefit. BMJ 2000; 321: 950–2PubMedCrossRef Heller RF, Dobson AJ. Disease impact number and population impact number: a population perspective to measures of risk and benefit. BMJ 2000; 321: 950–2PubMedCrossRef
12.
Zurück zum Zitat Heller RF, Dobson AJ, Attia J, et al. Impact numbers: measures of risk factor impact on the whole population from case control and cohort studies. J Epidemiol Community Health 2002; 56: 606–10PubMedCrossRef Heller RF, Dobson AJ, Attia J, et al. Impact numbers: measures of risk factor impact on the whole population from case control and cohort studies. J Epidemiol Community Health 2002; 56: 606–10PubMedCrossRef
13.
Zurück zum Zitat Attia J, Page JH, Heller RF, et al. Impact numbers in health policy decisions. J Epidemiol Community Health 2002; 56(8): 600–5PubMedCrossRef Attia J, Page JH, Heller RF, et al. Impact numbers in health policy decisions. J Epidemiol Community Health 2002; 56(8): 600–5PubMedCrossRef
14.
Zurück zum Zitat Heller RF, Edwards R, McElduff P. Implementing guidelines in primary care: can population impact measures help? BMC Public Health 2003; 3: 7PubMedCrossRef Heller RF, Edwards R, McElduff P. Implementing guidelines in primary care: can population impact measures help? BMC Public Health 2003; 3: 7PubMedCrossRef
15.
Zurück zum Zitat Heller RF, Buchan I, Edwards R, et al. Communicating risks at the population level: application of population impact numbers. BMJ 2003; 327(7424): 1162–5PubMedCrossRef Heller RF, Buchan I, Edwards R, et al. Communicating risks at the population level: application of population impact numbers. BMJ 2003; 327(7424): 1162–5PubMedCrossRef
16.
Zurück zum Zitat Cook R, Sackett D. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452–4PubMedCrossRef Cook R, Sackett D. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310: 452–4PubMedCrossRef
17.
Zurück zum Zitat Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10(8): 779–87PubMedCrossRef Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10(8): 779–87PubMedCrossRef
18.
Zurück zum Zitat Sendi PP, Briggs AH. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ 2001; 10(7): 675–80PubMedCrossRef Sendi PP, Briggs AH. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ 2001; 10(7): 675–80PubMedCrossRef
19.
Zurück zum Zitat Middleton E, Baker D. Comparison of social distribution of immunisation with measles, mumps, and rubella vaccine, England, 1991–2001. BMJ 2003; 326(7394): 854PubMedCrossRef Middleton E, Baker D. Comparison of social distribution of immunisation with measles, mumps, and rubella vaccine, England, 1991–2001. BMJ 2003; 326(7394): 854PubMedCrossRef
20.
Zurück zum Zitat Mitton C, Donaldson C. Health care priority setting: principles, practice and challenges. Cost Eff Resour Alloc 2004; 2(1): 3PubMedCrossRef Mitton C, Donaldson C. Health care priority setting: principles, practice and challenges. Cost Eff Resour Alloc 2004; 2(1): 3PubMedCrossRef
21.
Zurück zum Zitat Gemmell I, Heller RF, McElduff P, et al. Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease. J Epidemiol Community Health 2005; 59(12): 1041–6PubMedCrossRef Gemmell I, Heller RF, McElduff P, et al. Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease. J Epidemiol Community Health 2005; 59(12): 1041–6PubMedCrossRef
22.
Zurück zum Zitat Netten A, Curtis L. Unit costs of Health and Social Care 2003. Canterbury: Personal Social Services Research Unit, University of Kent, 2003 Netten A, Curtis L. Unit costs of Health and Social Care 2003. Canterbury: Personal Social Services Research Unit, University of Kent, 2003
23.
Zurück zum Zitat Wu LA, Kottke TE. Number needed to treat: caveat emptor. J Clin Epidemiol 2001; 54(2): 111–6PubMedCrossRef Wu LA, Kottke TE. Number needed to treat: caveat emptor. J Clin Epidemiol 2001; 54(2): 111–6PubMedCrossRef
24.
Zurück zum Zitat Kassai B, Gueyffier F, Boissel JP, et al. Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? J Clin Epidemiol 2003; 56(10): 977–82PubMedCrossRef Kassai B, Gueyffier F, Boissel JP, et al. Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit? J Clin Epidemiol 2003; 56(10): 977–82PubMedCrossRef
25.
Zurück zum Zitat Kristiansen IS, Gyrd-Hansen D. Cost-effectiveness analysis based on the number-needed-to-treat: common sense or nonsense? Health Econ 2004; 13(1): 9–19PubMedCrossRef Kristiansen IS, Gyrd-Hansen D. Cost-effectiveness analysis based on the number-needed-to-treat: common sense or nonsense? Health Econ 2004; 13(1): 9–19PubMedCrossRef
26.
Zurück zum Zitat Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeco-nomics 2003; 21(14): 991–1000CrossRef Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeco-nomics 2003; 21(14): 991–1000CrossRef
27.
Zurück zum Zitat Smith R, Richardson J. Can we estimate the ’social’ value of a QALY? Four core issues to resolve. Health Policy 2005 Sep 28; 74(1): 77–84PubMedCrossRef Smith R, Richardson J. Can we estimate the ’social’ value of a QALY? Four core issues to resolve. Health Policy 2005 Sep 28; 74(1): 77–84PubMedCrossRef
28.
Zurück zum Zitat Primatesta P. Prevalence of cardiovascular disease. Health Survey for England 1998. London: The Stationery Office, 1999 Primatesta P. Prevalence of cardiovascular disease. Health Survey for England 1998. London: The Stationery Office, 1999
29.
Zurück zum Zitat Capewell S, Livingston BM, MacIntyre K, et al. Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J 2000; 21(22): 1833–40PubMedCrossRef Capewell S, Livingston BM, MacIntyre K, et al. Trends in case-fatality in 117 718 patients admitted with acute myocardial infarction in Scotland. Eur Heart J 2000; 21(22): 1833–40PubMedCrossRef
30.
Zurück zum Zitat Freemantle N, Cleland J, Young P, et al. beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318(7200): 1730–7PubMedCrossRef Freemantle N, Cleland J, Young P, et al. beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318(7200): 1730–7PubMedCrossRef
31.
Zurück zum Zitat Critchley JA, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease (Cochrane Review). The Cochrane Library. 2nd ed. Chichester: John Wiley & Sons, 2004 Critchley JA, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease (Cochrane Review). The Cochrane Library. 2nd ed. Chichester: John Wiley & Sons, 2004
32.
Zurück zum Zitat Sarasin FP, Maschiangelo ML, Schaller MD, et al. Successful implementation of guidelines for encouraging the use of beta blockers in patients after acute myocardial infarction. Am J Med 1999; 106(5): 499–505PubMedCrossRef Sarasin FP, Maschiangelo ML, Schaller MD, et al. Successful implementation of guidelines for encouraging the use of beta blockers in patients after acute myocardial infarction. Am J Med 1999; 106(5): 499–505PubMedCrossRef
33.
Zurück zum Zitat Dudley NJ, Bowling A, Bond M, et al. Age- and sex-related bias in the management of heart disease in a district general hospital. Age Ageing 2002; 31(1): 37–42PubMedCrossRef Dudley NJ, Bowling A, Bond M, et al. Age- and sex-related bias in the management of heart disease in a district general hospital. Age Ageing 2002; 31(1): 37–42PubMedCrossRef
34.
Zurück zum Zitat Brotons C, Permanyer G, Pacheco V, et al. Prophylactic treatment after myocardial infarction in primary care: how far can we go? Fam Pract 2003; 20(1): 32–5PubMedCrossRef Brotons C, Permanyer G, Pacheco V, et al. Prophylactic treatment after myocardial infarction in primary care: how far can we go? Fam Pract 2003; 20(1): 32–5PubMedCrossRef
35.
Zurück zum Zitat Brotons C, Calvo F, Cascant P, et al. Is prophylactic treatment after myocardial infarction evidence-based? [published erratum appears in Fam Pract 1999 Feb; 16 (1): 94]. Fam Pract 1998 Oct; 15(5): 457–61PubMedCrossRef Brotons C, Calvo F, Cascant P, et al. Is prophylactic treatment after myocardial infarction evidence-based? [published erratum appears in Fam Pract 1999 Feb; 16 (1): 94]. Fam Pract 1998 Oct; 15(5): 457–61PubMedCrossRef
36.
Zurück zum Zitat Jolly K, Bradley F, Sharp S, et al. Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). BMJ 1999; 318(7185): 706–11PubMedCrossRef Jolly K, Bradley F, Sharp S, et al. Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). BMJ 1999; 318(7185): 706–11PubMedCrossRef
37.
Zurück zum Zitat Campbell NC, Thain J, Deans HG, et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998; 316(7142): 1430–4PubMedCrossRef Campbell NC, Thain J, Deans HG, et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998; 316(7142): 1430–4PubMedCrossRef
38.
Zurück zum Zitat Kotseva K, Wood D, De Backer G, et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22(7): 554–72CrossRef Kotseva K, Wood D, De Backer G, et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22(7): 554–72CrossRef
39.
Zurück zum Zitat Flanagan DEH, Cox P, Paine D, et al. Secondary prevention of coronary heart disease in primary care: a healthy heart initiative. QJM 1999; 92(5): 245–50PubMedCrossRef Flanagan DEH, Cox P, Paine D, et al. Secondary prevention of coronary heart disease in primary care: a healthy heart initiative. QJM 1999; 92(5): 245–50PubMedCrossRef
40.
Zurück zum Zitat Feder G, Griffiths C, Eldridge S, et al. Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial. BMJ 1999; 318(7197): 1522–6PubMedCrossRef Feder G, Griffiths C, Eldridge S, et al. Effect of postal prompts to patients and general practitioners on the quality of primary care after a coronary event (POST): randomised controlled trial. BMJ 1999; 318(7197): 1522–6PubMedCrossRef
41.
Zurück zum Zitat Fox KF, Wood DA, Wright M, et al. Evaluation of a cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease. J Cardiovasc Risk 2002; 9(6): 355–9PubMedCrossRef Fox KF, Wood DA, Wright M, et al. Evaluation of a cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease. J Cardiovasc Risk 2002; 9(6): 355–9PubMedCrossRef
42.
Zurück zum Zitat Hippisley-Cox J, Pringle M, Crown N, et al. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 2001; 322(7290): 832PubMedCrossRef Hippisley-Cox J, Pringle M, Crown N, et al. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ 2001; 322(7290): 832PubMedCrossRef
43.
Zurück zum Zitat Carroll K, Majeed A, Firth C, et al. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Public Health Med 2003; 25(1): 29–35PubMedCrossRef Carroll K, Majeed A, Firth C, et al. Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease register. J Public Health Med 2003; 25(1): 29–35PubMedCrossRef
45.
Zurück zum Zitat Simpson E, Beck C, Richard H, et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003; 145(3): 438–44PubMedCrossRef Simpson E, Beck C, Richard H, et al. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003; 145(3): 438–44PubMedCrossRef
46.
Zurück zum Zitat Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004; 117(2): 73–81PubMedCrossRef Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004; 117(2): 73–81PubMedCrossRef
47.
Zurück zum Zitat Corrigan M, Cupples ME, Stevenson M. Quitting and restarting smoking: cohort study of patients with angina in primary care. BMJ 2002; 324(7344): 1016–7PubMedCrossRef Corrigan M, Cupples ME, Stevenson M. Quitting and restarting smoking: cohort study of patients with angina in primary care. BMJ 2002; 324(7344): 1016–7PubMedCrossRef
Metadaten
Titel
Using economic analyses for local priority setting
The population cost-impact approach
verfasst von
Professor Richard F. Heller
Islay Gemmell
Edward C. F. Wilson
Richard Fordham
Richard D. Smith
Publikationsdatum
01.03.2006
Verlag
Springer International Publishing
Erschienen in
Applied Health Economics and Health Policy / Ausgabe 1/2006
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI
https://doi.org/10.2165/00148365-200605010-00006

Weitere Artikel der Ausgabe 1/2006

Applied Health Economics and Health Policy 1/2006 Zur Ausgabe

Current Opinion

Recycling blood